
Opinion|Videos|October 17, 2024
Overview of Idiopathic Pulmonary Fibrosis (IPF)
Author(s)Toby Maher, MD, PhD
Key Takeaways
- IPF is a chronic, progressive lung disease marked by lung tissue thickening and scarring, leading to reduced lung function.
- It is a specific type of interstitial lung disease, which includes various disorders affecting lung interstitium.
Toby Maher, MD, PhD, discusses how idiopathic pulmonary fibrosis (IPF) is a specific form of interstitial lung disease characterized by progressive lung scarring, which leads to significant respiratory impairment and distinct clinical challenges compared with other interstitial lung diseases.
Advertisement
Episodes in this series

Video content above is prompted by the following:
What is IPF, and how does IPF compare with interstitial lung disease?
Advertisement
Related to this article

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

San Francisco experts say earlier IgA nephropathy and FSGS detection depends on primary care education and care coordinators.

The FDA has approved secukinumab for PMR after the REPLENISH trial showed doubled sustained remission and lower steroid use vs a steroid taper alone.

Earlier MASH fibrosis detection is more urgent now that treatments exist, and automating FIB-4 in EHRs could help primary care, says Rohit Loomba, MD.

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

Neladalkib earned accelerated approval for previously treated ALK-positive NSCLC, with ORRs of 49% and 32%.

Non-US-born adults had higher CRC screening nonadherence than US-born adults, particularly those with less than 15 years of US residence.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Oral Giredestrant Regimen for ESR1-Mutated Breast Cancer
2
Hepatitis B Screening Gaps Persist as Functional Cure Option Arrives
3
IgA Nephropathy, FSGS Care Needs Coordinators, Not Just New Drugs
4
Complicated UTI Care Strained by Unclear Goals, Access Gaps
5



